Uptake and Tolerance of Chemotherapy in Elderly Patients with Small Cell Lung Cancer and Impact on Survival

Table 6

Adjusted¹ hazard ratio of death of patients 75 years or older diagnosed with SCLC in 2004–2008 in Alberta, Canada, who had an oncologist-consult².

	Adjusted^1 hazard; ratio (95% CI)	𝑃 value
ECOG Score		𝑃 = 0.02
0, 1, and 2	1
3 and 4	2.01 (1.22, 3.31)	0.007
Missing	1.59 (0.88, 2.88)	0.12
Stage		𝑃 = 0.33
Limited	1
Extensive	1.24 (0.80, 1.92)	0.33
Age at diagnosis		𝑃 = 0.80
75–79	1
≥80	1.06 (0.66, 1.75)	0.80
Co-morbidities		𝑃 = 0.05
0 or 1	1
2 or more	1.63 (1.00, 2.66)	0.05
Drug regimen		𝑃 = 0.82
Cisplatin/etoposide	1
Carboplatin/etoposide	1.15 (0.5, 2.65)	0.56
Oral etoposide	1.15 (0.71, 1.89)	0.75
Treatment status		𝑃 = 0.0018
Complete/full dose	1
Complete/reduced dose	1.02 (0.57, 1.82)	0.94
Not completed	2.72 (1.52, 4.87)	0.0007
No chemotherapy	2.01 (0.97, 4.18)	0.6

1Adjusted for all variables shown in the table.
²Start time was 12 weeks after the date of the initial oncologist-consult.